LianLian Reports 617 Million Yuan in H1 2024 Revenue, Up Over 40% Year-Over-Year

2024-08-27 LianLian HaiPress

HANGZHOU,China,Aug. 21,2024 -- On August 20,2024,Hong Kong-listed LianLian (2598.HK) announced its interim results for 2024.

According to the report,LianLian's transaction payment volume (TPV) in the first half of 2024 reached 1.57 trillion yuan,representing a year-on-year increase of 120.1%. During the same period,the company's total revenue rose 40.1% year-on-year to 617 million yuan. Gross profit also grew 20.3% year-on-year to 325 million yuan,with an overall gross profit margin of 52.6%. Additionally,the non-GAAP operating profit stood at 16.66 million yuan,showcasing LianLian's solid financial performance and robust operational capabilities.

Founded in 2009,LianLian's main business is divided into digital payment services and value-added services. The digital payment services encompass both global and domestic payments.

In the first half of this year,LianLian further expanded its global presence,enhanced product innovation,and drove comprehensive and outstanding growth across all business lines. During this period,the TPV of the global payment business reached 102.3 billion yuan,reflecting a year-on-year increase of 35.4%,while total revenue amounted to 372 million yuan,a year-on-year rise of 21.9%. The domestic payment business TPV soared to 1.47 trillion yuan,up 130.1% year-on-year,with total revenue hitting 170 million yuan,an increase of 117.8% year-on-year. Thanks to the traffic contribution from the growth of the digital payment business,total revenue from value-added services also increased 41.2% year-on-year to 67 million yuan.

In addition,in May of this year,LianLian obtained the EMI (Electronic Money Institution) license in Luxembourg. As of June 30,the company had established a global licensing network comprising 65 payment licenses and related qualifications. This allows LianLian to provide services in over 100 countries and regions,supporting transactions in more than 130 currencies.

Disclaimer: This article is reproduced from other media. The purpose of reprinting is to convey more information. It does not mean that this website agrees with its views and is responsible for its authenticity, and does not bear any legal responsibility. All resources on this site are collected on the Internet. The purpose of sharing is for everyone's learning and reference only. If there is copyright or intellectual property infringement, please leave us a message.

Newest

1US Olympic star Ilona Maher wows at Emmys before joining fellow Paris heroes Stephen Nedoroscik, Caeleb Dressel and Ezra Frech onstage

US Olympic star Ilona Maher wows at Emmys before joining fellow Paris heroes Stephen Nedoroscik, Caeleb Dressel and Ezra Frech onstage

2Who is Ryan Wesley Routh: Trump assassination attempt suspect voted for the former president before wishing he was 'gone', donated to Democrats and fought in Ukraine

Who is Ryan Wesley Routh: Trump assassination attempt suspect voted for the former president before wishing he was 'gone', donated to Democrats and fought in Ukraine

3See the disgraceful moment bloody brawl breaks out at Bulldogs vs Manly NRL final as man is hospitalised after fight that saw fans locked away for their own safety

See the disgraceful moment bloody brawl breaks out at Bulldogs vs Manly NRL final as man is hospitalised after fight that saw fans locked away for their own safety

4Josh Addo-Carr's 'very unusual' act leaves experts convinced he's about to be SACKED by the Bulldogs over cocaine scandal

Josh Addo-Carr's 'very unusual' act leaves experts convinced he's about to be SACKED by the Bulldogs over cocaine scandal

5Chengdu booming as global e-commerce hub

Chengdu booming as global e-commerce hub

6Gan & Lee Pharmaceuticals Presented Two Positive Clinical Results of Once-weekly Insulin GZR4 at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD 2024)

Gan & Lee Pharmaceuticals Presented Two Positive Clinical Results of Once-weekly Insulin GZR4 at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD 2024)

Links

©copyright 2009-2020 coinnews.vip